ACCC association of cancer care centers
Join/Renew
Login
Join/Renew
Login
Education & Resources
ACCC eXchange LogInCorporate Member Sponsored ResourcesPresentations & AbstractsACCC Connect eLearning LogIn
Publications
Oncology IssuesPatient Assistance & Reimbursement GuideTrending Now in Cancer CareBusiness Case Studies for Hiring New Staff
Events
2026 ACCC Leadership SummitAnnual Meeting & Cancer Center Business SummitCapitol Hill DayNational Oncology ConferenceOncology Reimbursement MeetingsOncology State Society Meetings
Policy & Advocacy
2024 Policy Wrap-Up and ACCC 2025 Policy PrioritiesLetters & StatementsAccess, Payment & Reimbursement ReformWhite Bagging & Brown BaggingAdvocacy ResourcesCancer Moonshot
Membership
Join | RenewWho We AreMembership Types & BenefitsCorporate MembersACCC Member Portal FAQMember Directory
Partners
Oncology State SocietiesPartner OrganizationsCME
News
News ReleasesAdvocacy News ReleasesOncology News
About ACCC
Timeline / 50th Anniversary2025 Impact ReportPresident's ThemeACCC Innovator AwardsACCC FellowsACCC Senior Staff
Breast CancerMetastatic Breast Cancer
Gastrointestinal CancerBiliary Tract CancerColorectal CancerGastric CancerLiver Cancer
Genitourinary CancerBladder CancerProstate CancerRenal Cell Carcinoma
Gynecologic CancerOvarian Cancer
Head & Neck Cancer
Hematologic MalignanciesAcute Lymphocytic Leukemia (ALL)Acute Myeloid Leukemia (AML)Chronic Lymphocytic Leukemia (CLL)Mantle Cell Lymphoma (MCL)Multiple Myeloma (MM)Myelodysplastic Syndromes (MDS)
Lung CancerNon-Small Cell Lung Cancer (NSCLC)Small Cell Lung Cancer (SCLC)
Sarcoma
Skin CancerMelanomaNon-Melanoma Skin Cancers (NMSC)
Clinical Practice & TreatmentCancer DiagnosticsCare CoordinationEHR Integration for Biomarker TestingQuality Improvement Collaboration: Integration of Precision Medicine in Community OncologyTreatment
Financial NavigationFAN Boot CampFinancial Advocacy Network (FAN) Resource LibraryPatient Assistance & Reimbursement GuidePrior Authorization
Health Equity & Access3, 2, 1, Go! Practical Solutions for Addressing Cancer Care DisparitiesAppalachian Community Cancer AllianceOncology Advanced PractitionersPersonalizing Care for Patients of All BackgroundsSocial Drivers of Health
Patient-Centered CareAddressing Care Disparities for VeteransAdolescent and Young Adult (AYA)Care Action Plans for People with CancerDermatologic ToxicitiesEmpowering CaregiversGeriatric OncologyHealth LiteracyNutritionOncology PharmacyPatient NavigationPsychosocial Care in OncologyShared Decision-MakingSupportive CareSurvivorship Care
Practice Management & OperationsCancer Program FundamentalsLeadership Sustainment and Engagement VideosOncology Practice Transformation and Integration CenterOncology Team Resiliency
ResearchACCC Community Oncology Research Institute (ACORI)
Technology & InnovationTelehealth & Digital Medicine
ACCCBuzz Blog
CANCER BUZZ Podcast
Oncology Issues
Join/Renew
Login
Breast CancerMetastatic Breast Cancer
Gastrointestinal CancerBiliary Tract CancerColorectal CancerGastric CancerLiver Cancer
Genitourinary CancerBladder CancerProstate CancerRenal Cell Carcinoma
Gynecologic CancerOvarian Cancer
Head & Neck Cancer
Hematologic MalignanciesAcute Lymphocytic Leukemia (ALL)Acute Myeloid Leukemia (AML)Chronic Lymphocytic Leukemia (CLL)Mantle Cell Lymphoma (MCL)Multiple Myeloma (MM)Myelodysplastic Syndromes (MDS)
Lung CancerNon-Small Cell Lung Cancer (NSCLC)Small Cell Lung Cancer (SCLC)
Sarcoma
Skin CancerMelanomaNon-Melanoma Skin Cancers (NMSC)
Clinical Practice & TreatmentCancer DiagnosticsCare CoordinationEHR Integration for Biomarker TestingQuality Improvement Collaboration: Integration of Precision Medicine in Community OncologyTreatment
Financial NavigationFAN Boot CampFinancial Advocacy Network (FAN) Resource LibraryPatient Assistance & Reimbursement GuidePrior Authorization
Health Equity & Access3, 2, 1, Go! Practical Solutions for Addressing Cancer Care DisparitiesAppalachian Community Cancer AllianceOncology Advanced PractitionersPersonalizing Care for Patients of All BackgroundsSocial Drivers of Health
Patient-Centered CareAddressing Care Disparities for VeteransAdolescent and Young Adult (AYA)Care Action Plans for People with CancerDermatologic ToxicitiesEmpowering CaregiversGeriatric OncologyHealth LiteracyNutritionOncology PharmacyPatient NavigationPsychosocial Care in OncologyShared Decision-MakingSupportive CareSurvivorship Care
Practice Management & OperationsCancer Program FundamentalsLeadership Sustainment and Engagement VideosOncology Practice Transformation and Integration CenterOncology Team Resiliency
ResearchACCC Community Oncology Research Institute (ACORI)
Technology & InnovationTelehealth & Digital Medicine
ACCCBuzz Blog
CANCER BUZZ Podcast
Oncology Issues
    • Education & Resources
    • Publications
    • Events
    • Policy & Advocacy
    • Membership
    • Partners
    • News
    • About ACCC
ACCC association of cancer care centers
1801 Research Boulevard, Suite 400, Rockville, MD 20850
Tel: 301.984.9496 Fax: 301.770.1949 Email Us
Contact UsVolunteers
Advertise
Career Center
Terms and Conditions
Privacy Policy
ACCC Rebranding
Copyright © 2026 Association of Cancer Care Centers. All Rights Reserved.
Advertisement
Home / Education And Resources / Clinical Practice Treatment / Cancer Diagnostics / Biomarkers / Biomarkerlive / Lexicon / References

REFERENCES

1 National Cancer Institute. NCI Dictionary of Cancer Terms. 2019. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms Accessed August 2019.

2 LUNGevity. What You Need to Know about Biomarker Testing. Chicago: LUNGevity Foundation; 2017.

3 Genetics Home Reference. What is DNA? Available at: https://ghr.nlm.nih.gov/primer/basics/dna Accessed August 2019.

4 Turski M. Driver and Passenger Mutations in Cancer Cell Genes. The Lundberg Institute. 2017; Available at http://lundberginstitute.043c1fe.netsolhost.com/driver-and-passenger-mutations-in-cancer-cell-genes/ Accessed August 2019.

5 National Cancer Institute. NCI Dictionary of Genetics Terms. Available at: https://www.cancer.gov/publications/dictionaries/genetics-dictionary Accessed August 2019.

6 American Society for Cytotechnology. What is a Cell Block? Available at: http://qac.asct.com/workbench/cell-block-basics/204/01 Accessed August 2019.

7 Dana-Farber Cancer Institute. Cell-Free DNA. Available at: https://www.dana-farber.org/research/departments-centers-and-labs/integrative-research-centers/center-for-cancer-genome-discovery/cell-free-dna/ Accessed August 2019.

8 Kulangara K, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of Pembrolizumab for treatment of gastric cancer. Arch Path Lab Med. 2019;143(3):330-337. https://doi.org/10.5858/arpa.2018-0043-OA

9 FDA. Companion Diagnostics. 2018. Available at: https://www.fda.gov/medical-devices/vitro-diagnostics/companion-diagnostics Accessed August 2019.

10 Foundation Medicine. Genomic Testing FAQ. 2019. Available at: https://www.foundationmedicine.com/pages/common-physicians-questions Accessed August 2019.

11 Mendoza D, Garcia CA. Defining research reproducibility: What do you mean? Clin Chem. 2017;63(11): 1777. Available at: http://clinchem.aaccjnls.org/content/63/11/1777 Accessed August 2019.

12 Croal B. The Communication of Critical and Unexpected Pathology Results. London: The Royal College of Pathologists; 2017. Available at: https://www.rcpath.org/uploads/assets/bb86b370-1545-4c5a-b5826a2c431934f5/The-communication-of-critical-and-unexpected-pathology-results.pdf Accessed August 2019.

13 National Cancer Institute. Tumor Markers in Common Use. 2019. Available at: https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-list Accessed August 2019.

14 American Association for Clinical Chemistry. Lab Tests Online. 2019. Available at: https://labtestsonline.org/articles/patient-tools Accessed August 2019.

15 NeoGenomics. BTK Inhibitor Acquired Resistance Panel. 2019. Available at: https://neogenomics.com/test-menu/btk-inhibitor-acquired-resistance-panel Accessed August 2019.

16 National Cancer Institute. BRCA Mutations: Cancer Risk and Genetic Testing. 2019. Available at: https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#q1 Accessed August 2019.

17 Naeim F, Rao PN, Son SX, Phan RT. Atlas of Hematology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches. 2nd ed. Elsevier, Inc.; 2018. https://doi.org/10.1016/C2015-0-05997-4.

18 Pernick N. CD25. Pathology Outlines. 2013. Available at: https://www.pathologyoutlines.com/topic/cdmarkerscd25.html Accessed August 2019.

19 Jain N, O’Brien S. Chronic Lymphocytic Leukemia with Deletion 17p: Emerging Treatment Options. 2012. Available at: https://www.cancernetwork.com/hematologic-malignancies/chronic-lymphocytic-leukemia-deletion-17p-emerging-treatment-options Accessed August 2019.

20 Helsten T, et al. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22(1):259-267. Available at: http://clincancerres.aacrjournals.org/content/22/1/259.full-text.pdf Accessed August 2019.

21 Genetics Home Reference. HRAS Gene. 2019. Available at: https://ghr.nlm.nih.gov/gene/HRAS# Accessed August 2019.

22 Roychowhurdy M. Stains: Ki67 / MIB1. Pathology Outlines. 2019. Available at: http://www.pathologyoutlines.com/topic/stainski67.html

23 Genetics Home Reference. MET Gene. Available at: https://ghr.nlm.nih.gov/gene/MET# Accessed August 2019.

24 Mayo Clinic Laboratories. MGMT Promoter Methylation, Tumor. 2019. Available at: https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/36733 Accessed August 2019.

25 Association of Oncology Nurse Navigators+. Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors. 2018. Available at: https://aonnonline.org/component/mams/?view=article&secid=180:faculty-perspectives-clinical-relevance-and-rationale-of-using-msi-h-dmmr-biomarkers-in-immunotherapy-of-colorectal-cancer-and-other-solid-tumors-part-3-of-a-4-part-series&artid=2068:clinical-relevance-and-rationale-of-using-msi-h-dmmr-biomarkers-in-immunotherapy-of-colorectal-cancer-and-other-solid-tumors Accessed August 2019.

26 Genetics Home Reference. MLH1 Gene. 2019. Available at: https://ghr.nlm.nih.gov/gene/MLH1#conditions Accessed August 2019.

27 Genetics Home Reference. NRAS Gene. 2019. Available at: https://ghr.nlm.nih.gov/gene/NRAS# Accessed August 2019.

28 Zhu J, et al. Is Neuron-specific enolase useful for diagnosing malignant pleural effusions? Evidence from a validated study and meta-analysis. BMC Cancer. 2017;17(590). https://doi.org/10.1186/s12885-017-3572-2

29 NeoGenomics. NTRK NGS Fusion Profile. 2019. Available at: https://neogenomics.com/test-menu/ntrk-ngs-fusion-profile Accessed August 2019.

30 NeoGenomics. p16. 2019. Available at: https://neogenomics.com/test-menu/p16 Accessed August 2019.

31 Genetics Home Reference. PIK3CA Gene. 2019. Available at: https://ghr.nlm.nih.gov/gene/PIK3CA# Accessed August 2019.

32 Genetics Home Reference. PTEN Gene. Available at: https://ghr.nlm.nih.gov/gene/PTEN#conditions Accessed October 2019.

33 Genetics Home Reference. RET Gene. 2019. Available at: https://ghr.nlm.nih.gov/gene/RET# Accessed August 2019.

34 My Cancer Genome. EGFR T790M. 2019. Available at: https://www.mycancergenome.org/content/alteration/egfr-t790m Accessed August 2019.

35 Dean L. Irinotecan Therapy and UGT1A1 Genotype. Medical Genetics Summaries [Internet]. Bethesda: National Center for Biotechnology Information; 2015. Available at: https://www.ncbi.nlm.nih.gov/books/NBK294473/ Accessed August 2019.

36 The Kennedy Institute of Ethics. Bioethics Blogs: Acting on “Actionable Mutations.” 2015. Available at: https://bioethics.georgetown.edu/2015/09/acting-on-actionable-mutations Accessed August 2019.